This study reveals that antioxidants can reverse oxidative stress in renal tissues, indicating potential therapeutic benefits for arsenic and chromium exposure.
Chromium (Cr) and arsenic (As) pose a threat to the exposed population, leading to various renal ailments. Although individual toxicity has been well investigated, little is known about their combined effects. In light of the mounting concern over the environmental impact of heavy metals, the current study investigated the potential benefits of the selected nutraceuticals, i.e., biochanin-A (BCA), coenzyme Q10 (CoQ10), and phloretin (PHL) in combined Cr + As intoxicated Swiss albino mice, providing a comprehensive understanding of the mechanism of action. During the two-week investigation, Cr (75 ppm) and As (100 ppm) were given orally to induce renal toxicity, and were simultaneously treated with BCA (50 mg/kg), CoQ10 (10 mg/kg), and PHL (50 mg/kg) intraperitoneally. The Cr + As-treated group showed an increase in kidney somatic index, metal burden, protein carbonylation, and malondialdehyde, along with a decrease in the activity of (superoxide dismutase, catalase, glutathione-S-transferase, reduced glutathione, and total thiol). Furthermore, DNA degradation, histology, and altered SIRT1/Nrf2/HO‑1/NQO1/SOD2/CYP1A1/KEAP1/CAS-8, and CAS-3 gene expressions corroborated the above findings. Alternatively, co-treatment with the selected antioxidants reversed the above mentioned parameters, highlighting the protective effects of these compounds against Cr + As-induced oxidative damage. Nrf2, a key player in this process, is responsible for the activation of the antioxidant response element and subsequent expression of antioxidant enzymes. We further investigated the possible interactions of BCA, CoQ10, and PHL with the antioxidant enzymes/proteins, SIRT1/Nrf2/KEAP1/HO-1/NQO1, using in silico studies. Our study offers new avenues for the future of chronic kidney disease treatment associated with Cr + As-induced exposure, providing a deeper understanding of the role of Nrf2 in this context.
No takes yet. Share an insight, caveat, or question.
Tripathi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: